Skip to content

Intra-articular Pulsed Radiofrequency With Steroids Injection Versus Intra-articular Steroids Injection in Chronic Sacroiliac Joint Arthritis

Comparison Between Intra-articular Pulsed Radiofrequency With Steroids Injection Versus Intra-articular Steroids Injection in Chronic Sacroiliac Joint Arthritis

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03564106
Enrollment
40
Registered
2018-06-20
Start date
2019-03-01
Completion date
2021-01-15
Last updated
2021-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain Management

Keywords

chronic sacroilitis,radiofrequancy,intraarticular steroids injection

Brief summary

The sacroiliac joint is Located between the pelvis and base of the spine, the sacroiliac joints are strong, stable joints that allow for little movement. While these joints do not bend like a knuckle or knee, they are susceptible to degenerative arthritis. Sacroiliac joint pain is one of the most common causes of chronic low back pain, accounting for 10% to 27% of patients with chronic lower back pain. It is known to be caused by abnormal motion in this joint, namely, too much motion or too little motion. Patients with pain experience various degrees of pain in the low back, groin, buttock, or posterior thigh.

Detailed description

The pain starts when the Sacroiliac joint gets inflamed. There are several reasons it could happen. It could be hurt when playing sports or if fall down. Sometimes start hurting when the ligaments that hold the SI joint together are damaged, which may make the joint move abnormally. The pain associated with sacroiliitis most commonly occurs in the buttocks and lower back. It can also affect the legs, groin and even the feet.

Interventions

DRUGintraarticular radiofrequency + intraarticular methylprednisolone

intraarticular radiofrequency + intraarticular methylprednisolone (30 mg)

DRUGintraarticular methylprednisolone

intraarticular methylprednisolone (30 mg)

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* All patients must have chronic pain more than 6 months and have failed medical treatment.

Exclusion criteria

* Infection at the site of injection * Opioids addiction * Coagulopathy or another bleeding diathesis * Those who refuse to participate in the study * Ankylosing Spondylitis patients

Design outcomes

Primary

MeasureTime frameDescription
pain intensityup to 6 monthsNumeric Rating Scale (NRS)

Secondary

MeasureTime frameDescription
Patient Impressionup to 6 monthsPatient Global Impression of Change Scale (PGIC)
Pain Disabilityup to 6 monthsPain Disability Index ( PDI)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026